[THE INVESTOR] Cell therapy developer Green Cross Cell and biotechnology firm ToolGen on Aug. 22 signed a memorandum of understanding on collaborating in developing immune therapy for cancer.
The two companies plan to apply ToolGen’s DNA scissor technology to Green Cross Cell’s anti-cancer immune therapy.
The companies hope to amplify T-cells’ ability to attack cancer cells.
cheesuk@heraldcorp.com
![[Exclusive] Ateez to return in November](https://wimg.heraldcorp.com/news/cms/2026/09/02/news-p.v1.20260902.76162fb0ba55493aad1c076f240d0750_R.jpg?type=h&h=120)